Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00107003 · ClinicalTrials.gov registry record · Phase 2
GW572016 to Treat Recurrent Malignant Brain Tumors
A Phase 2 study of Glioblastoma Multiforme and Glioma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT00107003 is a Phase 2 study of Glioblastoma Multiforme and Glioma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 9 participants, below the 97-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00107003, a Phase 2 study of Glioblastoma Multiforme and Glioma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will examine whether an experimental drug called GW572016 can delay tumor growth in patients with glioblastoma multiforme (GMB, a malignant brain tumor). GW572016 is believed to affect cancer cell function by interfering with the internal signaling needed for the cancer to grow. The study will also determine whether the presence of specific proteins in the tumor can predict what effects GW572016 will have on the tumor. Patients 18 years of age and older with GMB whose brain tumor does not respond to standard medical treatment and who can undergo surgery for their tumor may be eligible for this study. Candidates are screened with a physical examination and neurocognitive examination, blood tests, electrocardiogram (EKG), echocardiogram (ultrasound test of heart function) or MUGA scan (nuclear medicine test of heart function), magnetic resonance imaging (MRI) of the head, and computed tomography (CT) of the head. CT uses x-rays and MRI uses a magnetic field and radio waves to show brain structure. Participants undergo the following tests and procedures: * MRI and blood tests before surgery. * Surgery to remove the brain tumor. * Follow-up MRIs every 8 weeks after surgery. * Follow-up echocardiograms or MUGA scans every 8 weeks after surgery. * GW572016 treatment starting 7-10 days before surgery and continuing until the patient or doctor decides it is in the patient's best interest to stop it or until the tumor worsens. (The drug is stopped temporarily for surgery and a healing period after surgery.) * Blood tests every 2 weeks to evaluate the effects of GW572016 on the body. * Blood test before the first GW572016 treatment and at the time of surgery to assess the effect of the drug on the cells and to determine how much drug is present in the blood at the time of surgery. Participants are followed in clinic at least monthly while taking GW572016. While on treatment they keep a diary documenting their daily treatments. The diary is collected at the mont
Conditions Studied
Interventions
- DRUG lapatinib ditosylate
- PROCEDURE Adjuvant therapy
- PROCEDURE Conventional surgery
- PROCEDURE Neoadjuvant therapy
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2005-03-30 |
| Est. Completion | 2012-11-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00107003
The ClinicalTrials.gov registry entry for NCT00107003 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 97-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target (91% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Glioblastoma Multiforme appearing as the primary indexed condition, and to 4 interventions - of which lapatinib ditosylate is the first listed.
NCT00107003 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00107003 about?
NCT00107003 is a clinical study titled "GW572016 to Treat Recurrent Malignant Brain Tumors". This study will examine whether an experimental drug called GW572016 can delay tumor growth in patients with glioblastoma multiforme (GMB, a malignant brain tumor). GW572016 is believed to affect cancer cell function by interfering with the internal signaling needed for the cancer to grow. The study...
What is the current status of trial NCT00107003?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2005-03-30. Estimated completion is 2012-11-30.
What conditions does trial NCT00107003 study?
This clinical trial studies the following conditions: Glioblastoma Multiforme, Glioma, Brain Tumor, Gliosarcoma, GBM.
What interventions are being tested in trial NCT00107003?
The interventions under investigation include: lapatinib ditosylate (DRUG), Adjuvant therapy (PROCEDURE), Conventional surgery (PROCEDURE), Neoadjuvant therapy (PROCEDURE).
Who is sponsoring clinical trial NCT00107003?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00107003 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma Multiforme
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RECRUITING · Phase 2
-
hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)
RECRUITING · Phase 2
-
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
RECRUITING · Phase 2
-
A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment
RECRUITING · Phase 2
-
Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma
RECRUITING · Phase 2
-
Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.